Market Cap 758.32M
Revenue (ttm) 837.60M
Net Income (ttm) -127.30M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -15.20%
Debt to Equity Ratio 0.15
Volume 767,000
Avg Vol 1,281,548
Day's Range N/A - N/A
Shares Out 93.05M
Stochastic %K 55%
Beta 1.97
Analysts Sell
Price Target $7.68

Company Profile

Myriad Genetics, Inc., a molecular diagnostic testing and precision medicine company, develops and provides molecular tests. The company offers molecular diagnostic tests for oncology, women's health, and pharmacogenomics. It also provides MyRisk Hereditary Cancer test, a DNA sequencing test for assessing the risks for hereditary cancers; BRACAnalysis CDx Germline Companion Diagnostic test, a DNA sequencing test to help determine the therapy for metastatic breast, ovarian, metastatic pancreatic,...

Industry: Diagnostics & Research
Sector: Healthcare
Phone: 801 584 3600
Fax: 801 584 3640
Address:
322 North 2200 West, Salt Lake City, United States
SilentMove
SilentMove Oct. 5 at 1:05 PM
$MYGN Biotech with clinical catalyst. High volatility expected. Trading near cash value. Speculative positioning.
0 · Reply
PeakedSeller
PeakedSeller Oct. 3 at 8:15 PM
$MYGN $MYGN closed $8.06. Hold $7.85–8.00 and $8.20 → $8.8–9.2 is next; clear that and $10 stays live into Q3. Fundamentals still backing it (guide up, ~70% GM, EBITDA +). 📈
0 · Reply
TradingUK
TradingUK Oct. 3 at 2:26 PM
$MYGN Sold the remainder of my position today from an average of 4.80
2 · Reply
PeakedSeller
PeakedSeller Sep. 29 at 7:12 PM
$MYGN red on a green tape = profit-taking after first tag of $8. Watch $7.15–7.20 hold; reclaim $7.50 and the run at $8.8–$9.2 stays on deck. Fundamentals unchanged. 📈
0 · Reply
PeakedSeller
PeakedSeller Sep. 23 at 2:52 PM
$MYGN $MYGN x $SOPH = global liquid-biopsy CDx build (MSK-ACCESS). Strategic win (US regs + 800-site ex-US network), but no $$ today—so fade. Hold $7.5, push >$8.05, and $8.8–$9.2 stays on deck into Q3.
0 · Reply
PeakedSeller
PeakedSeller Sep. 19 at 4:55 PM
$MYGN this stock is only in the first steps of their redemption story. By the end of next year this company will get back to >20$ a share. By the end of this year I fully expect $10-12 per share after inline q3 results and continued optimism around pipeline and mental health testing growth
0 · Reply
PeakedSeller
PeakedSeller Sep. 19 at 4:53 PM
$MYGN fully expecting a move to >15$ a share by year end with data read outs and FDA filings this year. Cash runway into 2028 with no current debt burden and cash worth more than 3x their current market cap
1 · Reply
PeakedSeller
PeakedSeller Sep. 16 at 6:04 PM
0 · Reply
d00bie
d00bie Sep. 16 at 4:53 PM
$MYGN back to $13-$14 any day now
0 · Reply
ZacksResearch
ZacksResearch Sep. 16 at 12:40 PM
$MYGN down 74.5% in a year — is the decline overdone? 🤔 📉 Facing fierce competition and macro pressures 🧬 Yet, expanding in Oncology with innovative tests like Precise MRD Opportunity or trap? Full analysis here 👉 https://www.zacks.com/stock/news/2751944/is-it-a-prudent-move-to-retain-mygn-stock-in-your-portfolio-now?cid=sm-stocktwits-2-2751944-body-12548&ADID=SYND_STOCKTWITS_TWEET_2_2751944_BODY_12548
0 · Reply
Latest News on MYGN
Myriad Genetics Appoints Ben Wheeler Chief Financial Officer

Aug 18, 2025, 8:30 AM EDT - 2 months ago

Myriad Genetics Appoints Ben Wheeler Chief Financial Officer


Myriad Genetics, Inc. (MYGN) Q2 2025 Earnings Call Transcript

Aug 6, 2025, 4:14 AM EDT - 2 months ago

Myriad Genetics, Inc. (MYGN) Q2 2025 Earnings Call Transcript


Myriad Genetics, Inc. (MYGN) Q1 2025 Earnings Call Transcript

May 6, 2025, 11:35 PM EDT - 6 months ago

Myriad Genetics, Inc. (MYGN) Q1 2025 Earnings Call Transcript


Myriad Genetics Announces Inducement Awards

Apr 8, 2025, 4:15 PM EDT - 7 months ago

Myriad Genetics Announces Inducement Awards


Myriad Genetics, Inc. (MYGN) Q4 2024 Earnings Call Transcript

Feb 24, 2025, 8:03 PM EST - 8 months ago

Myriad Genetics, Inc. (MYGN) Q4 2024 Earnings Call Transcript


SilentMove
SilentMove Oct. 5 at 1:05 PM
$MYGN Biotech with clinical catalyst. High volatility expected. Trading near cash value. Speculative positioning.
0 · Reply
PeakedSeller
PeakedSeller Oct. 3 at 8:15 PM
$MYGN $MYGN closed $8.06. Hold $7.85–8.00 and $8.20 → $8.8–9.2 is next; clear that and $10 stays live into Q3. Fundamentals still backing it (guide up, ~70% GM, EBITDA +). 📈
0 · Reply
TradingUK
TradingUK Oct. 3 at 2:26 PM
$MYGN Sold the remainder of my position today from an average of 4.80
2 · Reply
PeakedSeller
PeakedSeller Sep. 29 at 7:12 PM
$MYGN red on a green tape = profit-taking after first tag of $8. Watch $7.15–7.20 hold; reclaim $7.50 and the run at $8.8–$9.2 stays on deck. Fundamentals unchanged. 📈
0 · Reply
PeakedSeller
PeakedSeller Sep. 23 at 2:52 PM
$MYGN $MYGN x $SOPH = global liquid-biopsy CDx build (MSK-ACCESS). Strategic win (US regs + 800-site ex-US network), but no $$ today—so fade. Hold $7.5, push >$8.05, and $8.8–$9.2 stays on deck into Q3.
0 · Reply
PeakedSeller
PeakedSeller Sep. 19 at 4:55 PM
$MYGN this stock is only in the first steps of their redemption story. By the end of next year this company will get back to >20$ a share. By the end of this year I fully expect $10-12 per share after inline q3 results and continued optimism around pipeline and mental health testing growth
0 · Reply
PeakedSeller
PeakedSeller Sep. 19 at 4:53 PM
$MYGN fully expecting a move to >15$ a share by year end with data read outs and FDA filings this year. Cash runway into 2028 with no current debt burden and cash worth more than 3x their current market cap
1 · Reply
PeakedSeller
PeakedSeller Sep. 16 at 6:04 PM
0 · Reply
d00bie
d00bie Sep. 16 at 4:53 PM
$MYGN back to $13-$14 any day now
0 · Reply
ZacksResearch
ZacksResearch Sep. 16 at 12:40 PM
$MYGN down 74.5% in a year — is the decline overdone? 🤔 📉 Facing fierce competition and macro pressures 🧬 Yet, expanding in Oncology with innovative tests like Precise MRD Opportunity or trap? Full analysis here 👉 https://www.zacks.com/stock/news/2751944/is-it-a-prudent-move-to-retain-mygn-stock-in-your-portfolio-now?cid=sm-stocktwits-2-2751944-body-12548&ADID=SYND_STOCKTWITS_TWEET_2_2751944_BODY_12548
0 · Reply
ZacksResearch
ZacksResearch Sep. 16 at 11:40 AM
$MYGN — growth story or dead weight? The company is expanding oncology testing and rolling out new diagnostics, but inflation and rising competition are clouding the outlook. Full bull/bear breakdown here 👉 https://www.zacks.com/stock/news/2751944/is-it-a-prudent-move-to-retain-mygn-stock-in-your-portfolio-now?cid=sm-stocktwits-2-2751944-teaser-12547&ADID=SYND_STOCKTWITS_TWEET_2_2751944_TEASER_12547
0 · Reply
PeakedSeller
PeakedSeller Sep. 11 at 9:57 PM
$MYGN closed $7.68—breakout held. Next gates $7.95–$8.20 then $8.8–$9.2. Strategy & margins intact (guide up, ~70% GM, EBITDA +). $9–10 into Q3 very much alive. 📈
0 · Reply
PeakedSeller
PeakedSeller Sep. 11 at 6:56 PM
$MYGN clear breakout🙌🏻
0 · Reply
ZacksResearch
ZacksResearch Sep. 8 at 12:19 PM
$MYGN — After a 75.5% plunge over the past year, is there a turnaround in sight? 🔍 🧬 New Phase 2 trial shows promise for Myriad Genetics' Precise MRD in ccRCC. The trial indicated that patients with low ctDNA levels might delay systemic treatments, potentially sparing them from side effects. 📉 Despite recent news, shares dropped 2.7%, but a strong Oncology expansion strategy could shift market sentiment. Discover what could drive MYGN's recovery 👉 https://www.zacks.com/stock/news/2747817/mygn-stock-might-gain-on-the-lancet-study-backing-precise-mrd?cid=sm-stocktwits-2-2747817-body-11229&ADID=SYND_STOCKTWITS_TWEET_2_2747817_BODY_11229
0 · Reply
ZacksResearch
ZacksResearch Sep. 8 at 11:19 AM
$MYGN could be setting up for a breakout 🚀 The Lancet just backed its Precise MRD with strong ctDNA detection results in oligometastatic ccRCC — a big validation for its oncology growth strategy. Full breakdown here 👉 https://www.zacks.com/stock/news/2747817/mygn-stock-might-gain-on-the-lancet-study-backing-precise-mrd?cid=sm-stocktwits-2-2747817-teaser-11228&ADID=SYND_STOCKTWITS_TWEET_2_2747817_TEASER_11228
0 · Reply
PeakedSeller
PeakedSeller Sep. 5 at 7:08 PM
$MYGN New meta-analysis (JCP) shows GeneSight improves remission +41% and response +30% vs TAU (n=3,532). Co confirms it’ll submit to payers. With price above $6.9, eyes on $7.5–8.2 next; clean Q3 keeps $9–10 in play. 📈🔬
0 · Reply
PeakedSeller
PeakedSeller Sep. 5 at 7:02 PM
$MYGN https://investor.myriad.com/news-releases/news-release-detail/26641/
2 · Reply
PeakedSeller
PeakedSeller Sep. 5 at 7:01 PM
$MYGN https://investor.myriad.com/news-releases/news-release-detail/26656/
0 · Reply
ZacksResearch
ZacksResearch Sep. 5 at 4:59 PM
$MYGN breakthrough in depression treatment — stock momentum next? 🚀 GeneSight just proved superior to treatment-as-usual in major depression, a result that could fuel wider adoption and investor interest. Full breakdown here 👉 https://www.zacks.com/stock/news/2747645/mygns-genesight-test-proven-superior-to-tau-stock-to-gain?cid=sm-stocktwits-2-2747645-teaser-11205&ADID=SYND_STOCKTWITS_TWEET_2_2747645_TEASER_11205
0 · Reply
ZacksResearch
ZacksResearch Sep. 5 at 3:59 PM
$MYGN making waves with its GeneSight Psychotropic test! 🌊 📊 Meta-analysis shows MDD patients in the GeneSight arm are 41% more likely to achieve remission and 30% more likely to achieve a response compared to TAU. 📈 Long-term EPS growth rate of 33.1%, compared with industry’s 21.1%. See what this means for Myriad Genetics' stock potential 👉 https://www.zacks.com/stock/news/2747645/mygns-genesight-test-proven-superior-to-tau-stock-to-gain?cid=sm-stocktwits-2-2747645-body-11172&ADID=SYND_STOCKTWITS_TWEET_2_2747645_BODY_11172
0 · Reply
v92
v92 Sep. 5 at 11:32 AM
$MYGN what a gem!!!!
0 · Reply
v92
v92 Sep. 2 at 7:41 PM
$MYGN So someone knows something. This is a prime M&A target!!!
1 · Reply